Latin America Point Of Care Infectious Disease Market
Размер рынка в млрд долларов США
CAGR :
% 
 Прогнозируемый период |
2022 –2029 |
 Размер рынка (базовый год) |
USD 1.30 Billion |
 Размер рынка (прогнозируемый год) |
USD 1.96 Billion |
 CAGR |
% |
| Основные игроки рынка |
Latin America Point of Care Infectious Disease Market, By Type (Products and Services), Technology (Immunodiagnostics, Molecular Diagnostics, Dipsticks, Microfluidics and Others), Application (Tropical Diseases, Sexually Transmitted Disease, Respiratory Disorders, Liver Disorders, Inflammatory Diseases, Hospital Acquired Infections (HAIS), GI Infections, CNS Infections, Cardiovascular Infection and Others), Availability (Over-the-Counter (OTC) Testing Kits and Prescription-Based Testing Kits), End Users (Homecare Setting, Hospitals, Diagnostic Centres, Outpatient Healthcare Setting and Others),Distribution Channel (Direct Tenders and Retail Sales) Industry Trends and Forecast to 2029
Market Analysis and Size
Testing that may be done in close proximity to the patient and allows a medical decision to be made immediately away based on the results and monitoring is known as point-of-care testing. Doctors can examine reliable real-time, lab-quality diagnostic data in minutes rather than hours using point-of-care testing (POCT), also known as with-patient testing. It ensures that patients receive the most effective and efficient treatment available, whenever and wherever they require it.
Data Bridge Market Research analyses that the point of care infectious disease market which was USD 1.3 billion in 2021, would rocket up to USD 1.96 billion by 2029, and is expected to undergo a CAGR of 5.24% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type (Products and Services), Technology (Immunodiagnostics, Molecular Diagnostics, Dipsticks, Microfluidics and Others), Application (Tropical Diseases, Sexually Transmitted Disease, Respiratory Disorders, Liver Disorders, Inflammatory Diseases, Hospital Acquired Infections (HAIS), GI Infections, CNS Infections, Cardiovascular Infection and Others), Availability (Over-the-Counter (OTC) Testing Kits and Prescription-Based Testing Kits), End Users (Homecare Setting, Hospitals, Diagnostic Centres, Outpatient Healthcare Setting and Others),Distribution Channel (Direct Tenders and Retail Sales) |
|
Countries Covered |
Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Abbott (U.S), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S), Siemens Healthcare Private Limited (Germany), Bio-Rad Laboratories, Inc. (U.S), Danaher (U.S), Sekisui Diagnostics (U.S), Trinity Biotech (Ireland), bioMérieux (France), EKF Diagnostics (Germany), AccuBioTech Co., Ltd. (China), Instrumentation Laboratory (U.S), Beckman Coulter, Inc. (U.S), PTS Diagnostics (U.S), Nova Biomedical (U.S), Chembio Diagnostics, Inc. (U.S), Quidel Corporation (U.S) and Sienco, Inc (U.S) |
|
Market Opportunities |
|
Market Definition
Point-of-care tests are not as popular as central laboratory testing, because of their limited volume and high cost. This places additional load on the billing system, as POC testing require different codes. This could lead to billing errors by unskilled or freshly employed staff and data entry failure due to mismatched test codes in the data management system.
Point of Care Infectious Disease Market Dynamics
Drivers
- Introduction of cost-effective technology
Over the projection period, cost-effective technology for efficient and accurate disease screening, diagnosis, and monitoring, together with government initiatives to restrict disease transmission and improve healthcare facilities, is likely to be a key driver.
- Increase in geriatric population
Furthermore, an increase in the senior population, which is more susceptible to infections and other ailments, is predicted to raise demand for healthcare monitoring and diagnostic devices in home care and assisted living. In addition, the incidence of diabetes, cardiac disease, drug misuse, and STDs in developing nations and the occurrence of chronic and endemic diseases like Chagas in less developed regions is predicted to boost market potential.
- Rise in infectious diseases
As the prevalence of infectious diseases in Latin America has increased, numerous healthcare organisations and governments have implemented screening programmes and plans to control and eradicate these diseases. The Latin America point of care diagnostics market is predicted to be driven by gradually developing economies, increased spending power among the population, high disease prevalence, and increased medical knowledge over the forecast period.
Opportunities
The whole point of care infectious disease market is expected to rise in the future as healthcare and medical professionals need more automated point of care infectious disease techniques. Government initiatives and measures promoting the benefits of point-of-care infectious illness could help to increase the point-of-care infectious disease business in the coming years. The point of care infectious disease business is seeing increased demand as people become more aware of the necessity of diagnostic tests and as their disposable incomes rise.
Restraints/Challenges
- Stringent regulatory policies
The point of care testing market shows sluggish growth due to the stringent and time-consuming regulatory policies. With the expanding area of use and increased adoption in developing economies, regulators are placing a greater emphasis on point-of-care testing (POCT) compliance, safety, and usability. Point-of-care testing are classed as class II medical devices by the US Food and Drug Administration. These devices provide a reasonable guarantee of the device's effectiveness and safety.
This point of care infectious disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the point of care infectious disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Covid-19 impact on Point of Care Infectious Disease Market
The growing use of point-of-care tests that can quickly identify COVID-19, the point-of-care diagnostics market will rise significantly in 2022. Point-of-care testing has become an important diagnostic technique due to the necessity for quick diagnostic results. Rapid antigen testing kits that can be utilised efficiently in point-of-care settings are in high demand due to the rapidly increasing number of COVID-19 cases and the growing pressure on governments to enhance patient management. Different significant reasons projected to fuel the long-term growth of the point-of-care diagnostics market are the rising prevalence of other respiratory disorders around the world, the shift toward decentralised diagnostics, and enhanced access to point-of-care devices through online platforms.
Recent Development
- In March 2020, Lumiradx Limited announced a collaborative agreement with Chembio Diagnostics to develop a covid 19 virus point-of-care diagnostic test. This collaboration will aid the company in establishing a foothold in a new market.
- In February 2020, Nanopin and ThermoFisher cooperated to improve infectious illness detection technologies. This partnership will give Thermofisher a new platform to expand its infectious illness point-of-care market.
Latin America Point of Care Infectious Disease Market Scope
The point of care infectious disease market is segmented on the basis of type, technology, availability, application, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Products
- Services
Technology
- Immunodiagnostics
- Molecular Diagnostics
- Dipsticks
- Microfluidics
- Others
Application
- Tropical Diseases
- Sexually Transmitted Disease
- Respiratory Disorders
- Liver Disorders
- Inflammatory Diseases
- Hospital Acquired Infections (HAIS)
- GI Infections
- CNS Infections
- Cardiovascular Infection
- Others
Availability
- Over-the-Counter (OTC) Testing Kits
- Prescription-Based Testing Kits
End Users
- Homecare Setting
- Hospitals
- Diagnostic Centres
- Outpatient Healthcare Setting
- Others
Distribution Channel
- Direct Tenders
- Retail Sales
Point of Care Infectious Disease Market Regional Analysis/Insights
The point of care infectious disease market is analysed and market size insights and trends are provided by country, type, technology, availability, application, distribution channel and end-user as referenced above.
The countries covered in the point of care infectious disease market report are Brazil, Argentina and Rest of South America as part of South America.
Brazil is dominating in the region due to high focus of government towards improvement of population health. The high prevalence of infectious diseases poses difficulties to authorities in achieving the goal of a healthy population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Point of Care Infectious Disease Market Share Analysis
The point of care infectious disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to point of care infectious disease market.
Some of the major players operating in the point of care infectious disease market are:
- Abbott (U.S)
- F. Hoffmann-La Roche Ltd (Switzerland)
- BD (U.S)
- Siemens Healthcare Private Limited (Germany)
- Bio-Rad Laboratories, Inc. (U.S)
- Danaher (U.S)
- Sekisui Diagnostics (U.S)
- Trinity Biotech (Ireland)
- bioMérieux (France)
- EKF Diagnostics (Germany)
- AccuBioTech Co., Ltd. (China)
- Instrumentation Laboratory (U.S)
- Beckman Coulter, Inc. (U.S)
- PTS Diagnostics (U.S)
- Nova Biomedical (U.S)
- Chembio Diagnostics, Inc. (U.S)
- Quidel Corporation (U.S)
- Sienco, Inc (U.S)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Интерактивная панель анализа данных
- Панель анализа компании для возможностей с высоким потенциалом роста
- Доступ аналитика-исследователя для настройки и запросов
- Анализ конкурентов с помощью интерактивной панели
- Последние новости, обновления и анализ тенденций
- Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Содержание
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 MARKET APPLICATION COVERAGE GRID
2.1 DBMR MARKET POSITION GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES
5.1.2 NEED FOR REDUCTION OF ANTIBIOTIC MISUSE
5.1.3 TECHNOLOGICAL ADVANCEMENTS IN POCT DEVICES
5.1.4 HIGH USAGE OF POCT DEVICES IN HOMECARE SETTINGS
5.1.5 INCLINATION TOWARDS EARLY AND QUICK DIAGNOSIS
5.2 RESTRAINTS
5.2.1 STRINGENT REGULATORY LANDSCAPE
5.2.2 UNFAVOURABLE REIMBURSEMENT SCENARIO
5.2.3 LACK OF AWARENESS REGARDING AVAILABILITY OF PRODUCTS
5.3 OPPORTUNITIES
5.3.1 POC TESTS WITH MULTIPLEXING CAPABILITIES
5.3.2 GROWING ACCEPTANCE OF COMPANION DIAGNOSTICS IN VARIOUS APPLICATIONS
5.4 CHALLENGES
5.4.1 RELUCTANCE TOWARDS CHANGING EXISTING DIAGNOSTIC PRACTICES
5.4.2 HIGH COST OF POCT AS COMPARED TO TRADITIONAL METHODS
6 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE
6.1 OVERVIEW
6.2 PRODUCTS
6.2.1 REAGENTS & KITS
6.2.1.1 HEMATOLOGY TESTING KITS
6.2.1.2 URINALYSIS TESTING KITS
6.2.1.3 INFLUENZA TESTING KITS
6.2.1.4 STD TESTING KITS
6.2.1.5 HIV TESTING KITS
6.2.1.6 OTHERS
6.2.2 EQUIPMENT
6.2.2.1 ANALYZERS
6.2.2.2 CONTAINERS
6.2.2.3 BAGS
6.2.2.4 COLLECTION TUBES
6.2.2.5 OTHERS
6.2.3 BIOMARKERS
6.2.3.1 BACTERIA
6.2.3.2 VIRUS
6.2.3.3 PARASITES
6.2.3.4 FUNGI
6.2.4 OTHERS
6.3 SERVICES
7 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY
7.1 OVERVIEW
7.2 IMMUNODIAGNOSTICS
7.2.1 RAPID TEST
7.2.2 ELISA
7.2.3 OTHERS
7.3 MOLECULAR DIAGNOSTICS
7.4 DIPSTICKS
7.5 MICROFLUIDICS
7.6 OTHERS
8 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 TROPICAL DISEASES
8.3 SEXUALLY TRANSMITTED DISEASE
8.4 RESPIRATORY DISORDERS
8.5 LIVER DISORDERS
8.6 INFLAMMATORY DISEASES
8.7 HOSPITAL ACQUIRED INFECTIONS (HAIS)
8.8 GI INFECTIONS
8.9 CNS INFECTIONS
8.1 CARDIOVASCULAR INFECTION
8.11 OTHERS
9 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY
9.1 OVERVIEW
9.2 OVER-THE-COUNTER (OTC) TESTING KITS
9.3 PRESCRIPTION-BASED TESTING KITS
10 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS
10.1 OVERVIEW
10.2 HOSPITALS
10.3 OUTPATIENT HEALTHCARE SETTING
10.4 HOMECARE SETTING
10.5 OTHERS
11 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDERS
11.3 RETAIL SALES
12 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY COUNTRY
12.1 BRAZIL
12.2 MEXICO
12.3 ARGENTINA
12.4 COLOMBIA
12.5 CHILE
12.6 PERU
12.7 ECUADOR
12.8 REST OF LATIN AMERICA
13 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, COMPANY LANDSCAPE
14 SWOT ANALYSIS
14.1 STRENGTH: -
14.1.1 SIGNIFICANT INCREASING SHARES IN MARKET FOCUSED SEGMENT
14.1.2 STRONG GLOBAL PRESENCE
14.2 WEAKNESS: - LOW R&D INVESTMENTS
14.3 OPPORTUNITY: - INITIATIVES FOR EXPANDING BUSINESS
14.3.1 THREAT: - CURRENCY CONVERSION
14.4 DATA BRIDGE MARKET RESEARCH ANALYSIS
15 CONCLUSION
16 QUESTIONNAIRE
17 RELATED REPORTS
Список таблиц
LIST OF TABLES
TABLE 1 MULTIPLEXING PLATFORMS MANUFATURED BY DIFFERENT COMPANIES FOR DETECTION OF INFECTIOUS DISEASES
TABLE 2 TEST COSTS (USD) BY TEST PROCEDURE AND TESTING REGIME
TABLE 3 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 4 LATIN AMERICA PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 5 LATIN AMERICA REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 6 LATIN AMERICA EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 7 LATIN AMERICA BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 8 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 9 LATIN AMERICA IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 10 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 11 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION)
TABLE 12 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION)
TABLE 13 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 14 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 15 BRAZIL POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 16 BRAZIL PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 17 BRAZIL REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 18 BRAZIL REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS)
TABLE 19 BRAZIL EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 20 BRAZIL BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 21 BRAZIL POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 22 BRAZIL IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 23 BRAZIL POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 24 BRAZIL POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION)
TABLE 25 BRAZIL POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION)
TABLE 26 BRAZIL POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 27 MEXICO POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 28 MEXICO PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 29 MEXICO REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 30 MEXICO REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS)
TABLE 31 MEXICO EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 32 MEXICO BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 33 MEXICO POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 34 MEXICO IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 35 MEXICO POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 36 MEXICO POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION)
TABLE 37 MEXICO POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION)
TABLE 38 MEXICO POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 39 ARGENTINA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 40 ARGENTINA PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 41 ARGENTINA REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 42 ARGENTNA REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS)
TABLE 43 ARGENTINA EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 44 ARGENTINA BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 45 ARGENTINA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 46 ARGENTINA IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 47 ARGENTINA POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 48 ARGENTINA POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION)
TABLE 49 ARGENTINA POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION)
TABLE 50 ARGENTINA POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 51 COLOMBIA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 52 COLOMBIA PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 53 COLOMBIA REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 54 COLOMBIA REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS)
TABLE 55 COLOMBIA EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 56 COLOMBIA BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 57 COLOMBIA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 58 COLOMBIA IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 59 COLOMBIA POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 60 COLOMBIA POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION)
TABLE 61 COLOMBIA POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION)
TABLE 62 COLOMBIA POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 63 CHILE POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 64 CHILE PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 65 CHILE REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 66 CHILE REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS)
TABLE 67 CHILE EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 68 CHILE BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 69 CHILE POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 70 CHILE IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 71 CHILE POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 72 CHILE POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION)
TABLE 73 CHILE POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION)
TABLE 74 CHILE POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 75 PERU POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 76 PERU PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 77 PERU REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 78 PERU REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS)
TABLE 79 PERU EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 80 PERU BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 81 PERU POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 82 PERU IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 83 PERU POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 84 PERU POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION)
TABLE 85 PERU POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION)
TABLE 86 PERU POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 87 ECUADOR POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 88 ECUADOR PRODUCTS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 89 ECUADOR REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 90 ECUADOR REAGENTS & KITS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (UNITS)
TABLE 91 ECUADOR EQUIPMENT IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 92 ECUADOR BIOMARKERS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
TABLE 93 ECUADOR POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 94 ECUADOR IMMUNODIAGNOSTICS IN POINT OF CARE INFECTIOUS DISEASE MARKET, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 95 ECUADOR POINT OF CARE INFECTIOUS DISEASE MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 96 ECUADOR POINT OF CARE INFECTIOUS DISEASE MARKET, BY AVAILABILITY, 2018-2027 (USD MILLION)
TABLE 97 ECUADOR POINT OF CARE INFECTIOUS DISEASE MARKET, BY END USERS, 2018-2027 (USD MILLION)
TABLE 98 ECUADOR POINT OF CARE INFECTIOUS DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 99 REST OF LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET, BY TYPE, 2018-2027 (USD MILLION)
Список рисунков
LIST OF FIGURES
FIGURE 1 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: SEGMENTATION
FIGURE 2 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: DATA TRIANGULATION
FIGURE 3 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: DROC ANALYSIS
FIGURE 4 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET : REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: DBMR MARKET POSITION GRID
FIGURE 9 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE : VENDOR SHARE ANALYSIS
FIGURE 10 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF INFECTIOUS DISEASE AND NEED FOR REDUCTION OF ANTIBIOTIC USE ARE DRIVING THE LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 12 PRODUCTS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET IN 2020 & 2027
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET
FIGURE 14 GENERAL PROCESS OF MEDICAL DEVICE REGULATION BY THE FEDERAL COMMISSION FOR THE PROTECTION AGAINST SANITARY RISK (COFEPRIS) IN MEXICO
FIGURE 15 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TYPE, 2019
FIGURE 16 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TYPE, 2019-2027 (USD MILLION)
FIGURE 17 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 18 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TECHNOLOGY, 2019
FIGURE 20 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TECHNOLOGY, 2019-2027 (USD MILLION)
FIGURE 21 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TECHNOLOGY, CAGR (2020-2027)
FIGURE 22 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 23 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY APPLICATION, 2019
FIGURE 24 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY APPLICATION, 2019-2027 (USD MILLION)
FIGURE 25 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY APPLICATION, CAGR (2020-2027)
FIGURE 26 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 27 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY AVAILABILITY, 2019
FIGURE 28 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY AVAILABILITY, 2019-2027 (USD MILLION)
FIGURE 29 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY AVAILABILITY, CAGR (2020-2027)
FIGURE 30 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY AVAILABILITY, LIFELINE CURVE
FIGURE 31 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY END USERS, 2019
FIGURE 32 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY END USERS, 2019-2027 (USD MILLION)
FIGURE 33 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY END USERS, CAGR (2020-2027)
FIGURE 34 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY END USERS, LIFELINE CURVE
FIGURE 35 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 36 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)
FIGURE 37 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY DISTRIBUTION CHANNEL CAGR (2020-2027)
FIGURE 38 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 39 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: SNAPSHOT (2019)
FIGURE 40 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY COUNTRY (2019)
FIGURE 41 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY COUNTRY (2020 & 2027)
FIGURE 42 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY COUNTRY (2019 & 2027)
FIGURE 43 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: BY TYPE (2020-2027)
FIGURE 44 LATIN AMERICA POINT OF CARE INFECTIOUS DISEASE MARKET: COMPANY SHARE 2019 (%)
Методология исследования
Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.
Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.
Доступна настройка
Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.
